BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 21, 2021
Product Development

Jan. 20 Quick Takes: AZ, Daiichi get Enhertu approvals in gastric, breast cancer; plus EdiGene, Merck, Oxford, BMS and Omeros

Partners AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) said HER2-targeted antibody-drug conjugate (ADC) Enhertu fam-trastuzumab deruxtecan-nxki received two additional approvals this week. On Tuesday, FDA approved an sBLA for Enhertu to treat locally...
BioCentury | Jan 13, 2021
Product Development

Why Verve chose base editing over standard CRISPR for its lead CV candidate

Verve’s non-human primate data makes the case that base editing can produce durable and efficient changes in protein production by the liver, with a clear route to protection from heart attack. Six-month data shared by...
BioCentury | Dec 1, 2020
Emerging Company Profile

Spotlight: solving CRISPR’s delivery challenges with RNPs

Spotlight emerged from stealth on Monday with a $30 million series A round led by GV and a platform that could help address the challenge of systemically delivering CRISPR-based gene editing therapies...
BioCentury | Nov 20, 2020
Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

A deal with Lilly delivering $135 million up front will allow Precision BioSciences to derive immediate value from the in vivo gene correction application of its ARCUS platform, which has lagged its clinical pipeline of...
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

LifeEDIT debuted with undisclosed funding from ElevateBio and former parent company AgBiome this week to develop novel RNA-guided nucleases and base editors that could offer broader genome access than...
BioCentury | Nov 14, 2020
Emerging Company Profile

Metagenomi hunts for new gene editing systems with $65M series A

Metagenomi is systematizing the search for new gene editing tools by scouring the genomes of bacteria in ecological samples. The company emerged from stealth Thursday with a $65 million series A round...
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

This year’s ASH meeting provides an opportunity to take stock of clinical progress in hot target, modality and disease areas: CD47 inhibitors, allogeneic CAR T cells and sickle cell disease. Abstracts...
BioCentury | Nov 12, 2020
Product Development

Lining up allogeneic CAR Ts at ASH: Data Byte

Promising efficacy data from China’s Bioheng are among the allogeneic CAR T cell updates at ASH this year.  The past year has seen a growing number of clinical readouts for off-the-shelf allogeneic...
BioCentury | Nov 11, 2020
Product Development

In vivo gene editing advances with Intellia’s trial start, grant

Intellia took CRISPR-based in vivo gene editing two steps forward this week with the start of the first clinical trial of a systemically delivered therapy and the announcement that the biotech was...
Items per page:
1 - 10 of 609